Drugs / NTR-101
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06750588 Comparator | Nov 2025 → Apr 2026 overdue | alcoholic hepatitis | Nterica Bio inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTR-101 | “NTR-101 is a product developed for oral delivery and composed of natural bacteriophages that specifically target cytolysin-positive E. faecalis.” NCT06750588 ↗ |
| Route | Oral | “NTR-101 will be given orally to participants once daily for 7 days” NCT06750588 ↗ |